163 related articles for article (PubMed ID: 8394192)
1. A clinical trial on the effects of a combination of elcatonin (carbocalcitonin) and conjugated estrogens on vertebral bone mass in early postmenopausal women.
Meschia M; Brincat M; Barbacini P; Crossignani PG; Albisetti W
Calcif Tissue Int; 1993 Jul; 53(1):17-20. PubMed ID: 8394192
[TBL] [Abstract][Full Text] [Related]
2. Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women.
Meschia M; Brincat M; Barbacini P; Maini MC; Marri R; Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 1992 Oct; 47(1):53-7. PubMed ID: 1330761
[TBL] [Abstract][Full Text] [Related]
3. Prevention of osteoporosis by medroxyprogesterone acetate in postmenopausal women.
McNeeley SG; Schinfeld JS; Stovall TG; Ling FW; Buxton BH
Int J Gynaecol Obstet; 1991 Mar; 34(3):253-6. PubMed ID: 1673944
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis].
Wu Y; Liu J; Xing S; Xu R; Zhang Z; Wang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 May; 37(5):267-70. PubMed ID: 12133397
[TBL] [Abstract][Full Text] [Related]
5. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
Osteoporos Int; 2005 Apr; 16(4):372-9. PubMed ID: 15654581
[TBL] [Abstract][Full Text] [Related]
6. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Hosking D; Chilvers CE; Christiansen C; Ravn P; Wasnich R; Ross P; McClung M; Balske A; Thompson D; Daley M; Yates AJ
N Engl J Med; 1998 Feb; 338(8):485-92. PubMed ID: 9443925
[TBL] [Abstract][Full Text] [Related]
7. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen.
Gallagher JC; Kable WT; Goldgar D
Am J Med; 1991 Feb; 90(2):171-8. PubMed ID: 1847582
[TBL] [Abstract][Full Text] [Related]
8. Effects of the combined use of calcitonin and 1 alpha-hydroxycholecalciferol on vertebral bone loss and bone turnover in women with postmenopausal osteopenia and osteoporosis: a prospective study of long-term and continuous administration with low dose calcitonin.
Ushiroyama T; Ikeda A; Sakai M; Higashiyama T; Ueki M
Maturitas; 2001 Dec; 40(3):229-38. PubMed ID: 11731184
[TBL] [Abstract][Full Text] [Related]
9. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial.
Recker RR; Davies KM; Dowd RM; Heaney RP
Ann Intern Med; 1999 Jun; 130(11):897-904. PubMed ID: 10375338
[TBL] [Abstract][Full Text] [Related]
10. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
Gambacciani M; Ciaponi M; Cappagli B; Genazzani AR
Am J Obstet Gynecol; 2001 Nov; 185(5):1180-5. PubMed ID: 11717654
[TBL] [Abstract][Full Text] [Related]
11. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.
Lindsay R; Gallagher JC; Kleerekoper M; Pickar JH
JAMA; 2002 May 22-29; 287(20):2668-76. PubMed ID: 12020302
[TBL] [Abstract][Full Text] [Related]
12. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.
Greenspan SL; Emkey RD; Bone HG; Weiss SR; Bell NH; Downs RW; McKeever C; Miller SS; Davidson M; Bolognese MA; Mulloy AL; Heyden N; Wu M; Kaur A; Lombardi A
Ann Intern Med; 2002 Dec; 137(11):875-83. PubMed ID: 12458987
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
Greenspan SL; Resnick NM; Parker RA
JAMA; 2003 May; 289(19):2525-33. PubMed ID: 12759324
[TBL] [Abstract][Full Text] [Related]
14. Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial.
Civitelli R; Pilgram TK; Dotson M; Muckerman J; Lewandowski N; Armamento-Villareal R; Yokoyama-Crothers N; Kardaris EE; Hauser J; Cohen S; Hildebolt CF
Arch Intern Med; 2002 Jun; 162(12):1409-15. PubMed ID: 12076241
[TBL] [Abstract][Full Text] [Related]
15. Do estrogens improve bone mass in osteoporotic women over ten years of menopause.
Szejnfeld VL; Souen JS; Baracat EC; Atra E; de Lima GR
Sao Paulo Med J; 1994; 112(1):517-21. PubMed ID: 7871318
[TBL] [Abstract][Full Text] [Related]
16. Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT.
Morishige K; Yamamoto T; Sawada K; Ohmichi M; Tasaka K; Murata Y
Arch Gynecol Obstet; 2003 Jun; 268(2):105-6. PubMed ID: 12768299
[TBL] [Abstract][Full Text] [Related]
17. The effects of hormonal replacement therapy on insulin sensitivity in surgically postmenopausal cynomolgus monkeys (Macaca fascicularis).
Cefalu WT; Wagner JD; Bell-Farrow AD; Wang ZQ; Adams MR; Toffolo G; Cobelli C
Am J Obstet Gynecol; 1994 Aug; 171(2):440-5. PubMed ID: 8059824
[TBL] [Abstract][Full Text] [Related]
18. Prevention of postmenopausal bone loss with exchange for short-term HRT for 1alpha-hydroxycholecalciferol.
Ushiroyama T; Ikeda A; Sakai M; Higashiyama T; Ueki M
Maturitas; 2003 Jun; 45(2):119-27. PubMed ID: 12787970
[TBL] [Abstract][Full Text] [Related]
19. Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women.
Orr-Walker BJ; Evans MC; Clearwater JM; Horne A; Grey AB; Reid IR
Arch Intern Med; 2000 Jul; 160(14):2161-6. PubMed ID: 10904459
[TBL] [Abstract][Full Text] [Related]
20. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ; Gillespie JA
Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
